Publicaciones en colaboración con investigadores/as de University of Leicester (61)

2023

  1. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

    Kidney International, Vol. 103, Núm. 2, pp. 391-402

2022

  1. Mapping genomic loci implicates genes and synaptic biology in schizophrenia

    Nature, Vol. 604, Núm. 7906, pp. 502-508

  2. Prevalence and Disease Spectrum of Extracoronary Arterial Abnormalities in Spontaneous Coronary Artery Dissection

    JAMA Cardiology, Vol. 7, Núm. 2, pp. 159-166

2021

  1. A European Research Agenda for Geriatric Emergency Medicine: a modified Delphi study

    European Geriatric Medicine, Vol. 12, Núm. 2, pp. 413-422

  2. Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data

    Cardiovascular Diabetology, Vol. 20, Núm. 1

  3. Electrocardiographic Imaging for Atrial Fibrillation: A Perspective From Computer Models and Animal Experiments to Clinical Value

    Frontiers in Physiology, Vol. 12

  4. Inhaled nitric oxide (iNO) for preventing prematurity-related bronchopulmonary dysplasia (BPD): 7-year follow-up of the European Union Nitric Oxide (EUNO) trial

    Journal of Perinatal Medicine, Vol. 49, Núm. 1, pp. 104-110

  5. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. Delusional parasitosis in multiple sclerosis: An enigmatic manifestation of a multifaceted disease

    Neurologia

  2. Evaluation and Management of Nonculprit Lesions in STEMI

    JACC: Cardiovascular Interventions, Vol. 13, Núm. 10, pp. 1145-1154

  3. Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool

    Kidney International, Vol. 98, Núm. 4, pp. 1009-1019

  4. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study

    The Lancet Diabetes and Endocrinology, Vol. 8, Núm. 1, pp. 27-35

  5. Memory and Executive Dysfunction Predict Complex Activities of Daily Living Impairment in Amnestic Multi-Domain Mild Cognitive Impairment

    Journal of Alzheimer's disease : JAD, Vol. 75, Núm. 3, pp. 1061-1069

2019

  1. Derivation and Validation of a Chronic Total Coronary Occlusion Intervention Procedural Success Score From the 20,000-Patient EuroCTO Registry: The EuroCTO (CASTLE) Score

    JACC: Cardiovascular Interventions, Vol. 12, Núm. 4, pp. 335-342

  2. Metabolic Syndrome in Heart Failure: Friend or Foe?

    Heart Failure Clinics, Vol. 15, Núm. 3, pp. 349-358

  3. Screening of extra-coronary arteriopathy with magnetic resonance angiography in patients with spontaneous coronary artery dissection: A single-centre experience

    Cardiovascular Diagnosis and Therapy, Vol. 9, Núm. 3, pp. 229-238

2018

  1. SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL

    Journal of the American College of Cardiology, Vol. 71, Núm. 22, pp. 2497-2506

2017

  1. Arterial Remodeling After Bioresorbable Scaffolds and Metallic Stents

    Journal of the American College of Cardiology, Vol. 70, Núm. 1, pp. 60-74

  2. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial

    The Lancet, Vol. 389, Núm. 10084, pp. 2117-2127

2016

  1. A comparison study of cognitive deficits in radiologically and clinically isolated syndromes

    Multiple Sclerosis, Vol. 22, Núm. 2, pp. 250-253